Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- FDA Accepts Astellas/Seagen’s Submissions for Padcev’s Full Approval, Label Expansion
April 21, 2021
- Oncolys to Codevelop COVID-19 Med with Shin Nippon Biomedical
April 21, 2021
- Life Science Institute to Begin Exploratory Study of Muse Cell Therapy for COVID-19-Associated ARDS
April 21, 2021
- New Grad Hiring Down 3.3% at 55 Drug Makers, Sales Rep Opportunities Fall amid DX: Survey
April 20, 2021
- Bayer’s Japan Sales Sag 5%, but Targets Reached in 2020
April 19, 2021
- Kobayashi Kako Chief Sorry for Fake Application Documents; Third-Party Report Reveals New Problems
April 19, 2021
- Takeda, Nihon Pharm to Discuss Integration of Plasma Businesses
April 19, 2021
- Fujifilm Holdings Aims to Ring Up Healthcare Sales of 860 Billion Yen in FY2023: 3-Year Biz Plan
April 19, 2021
- High Court Backs Positive Ruling for Shionogi in Osaka Tax Suit
April 16, 2021
- Towa Files Additional Request for Livalo Patent Invalidity in December 2020
April 16, 2021
- Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
April 15, 2021
- Rohto Licenses COVID-19 Drug Candidate from Japan Biotech
April 15, 2021
- Ono Files Opdivo for Cancer of Unknown Primary in Japan
April 15, 2021
- Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief
April 14, 2021
- Kyowa Kirin Commences Japan PIII of NHE3 Inhibitor for Hyperphosphatemia
April 14, 2021
- Otsuka, Lundbeck to Carry On Multinational PIII of Brexpiprazole for Agitation in Alzheimer’s
April 14, 2021
- Urovant’s OAB Med Gemtesa Now Available in US
April 14, 2021
- Kobayashi Kako Recalling 4 Mesalazine Products due to OOS
April 14, 2021
- Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
April 13, 2021
- Nipro Gets Approval of Seven-Dose Syringe for Pfizer COVID-19 Vaccine
April 13, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…